Extended Data Fig. 2: Cell-based assays with 1A5 CLAMP.
From: Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors
(a) No observable KRAS staining by 1A5 CLAMP in HCT116 KRASG13D cells treated with a KRASG12C inhibitor GNE-1952. Scale bar: 200 μM. Results are representative of 2 independent experiments. (b) Immunoblot analysis for covalently modified KRAS and KRAS pathway markers (pERK, pMEK, and pS6) in a bulk population of HCC1171 KRASG12C mutant cancer cells. Washout experiments reveals that KRASG12C covalent modification is maintained for 24 hours after removal of ARS-853. Scale bar: 200 μM. Results are representative of 2 independent experiments. (c) Gating strategy for FACs experiments in Fig. 2e.
